<DOC>
	<DOCNO>NCT02466204</DOCNO>
	<brief_summary>A prospective , randomize , control study explore efficacy safety use either corifollitropin alfa 150 mcg daily recombinant follicle stimulation hormone ( FSH ) 300 international unit ( IU ) stimulation treatment subject undergo control ovarian stimulation prior IVF . The study design non-inferiority trial . The sample size trial 400 subject , group , treat one IVF cycle base upon primary endpoint number oocytes retrieve .</brief_summary>
	<brief_title>Efficacy Corifollitropin Alfa Versus Follitropin Beta Aged IVF ( In-vitro Fertilization ) Patients</brief_title>
	<detailed_description>Stimulation regimen assist reproductive technology procedure Corifollitropin Alfa Group : On day 2 day 3 menstrual cycle , single subcutaneous injection corifollitropin alfa 150 mg/ 0.5 mL administer ( stimulation day 1 ) . FSH Group : Daily subcutaneous injection recombinant FSH ( Follitropin Beta ) 300 international unit ( IU ) start On day 2 day 3 menstrual cycle ( stimulation day 1 ) continue include stimulation day 7 . From stimulation day 8 onwards , subject treatment group continue daily subcutaneous dose FSH day human chorionic gonadotropin ( hCG ) administration gonadotropin release hormone agonist administration day . The maximum FSH dose continue treatment first 7 day 300 IU , dose could reduce desire . To prevent premature luteinizing hormone ( LH ) surge gonadotropin release hormone ( GnRH ) antagonist ( ganirelix acetate subcutaneous injection , 0.25 mg/ 0.5 mL ) administer , start stimulation day 5 . As soon least three follicle 17 mm observe ultrasound , hCG GnRH agonist use final oocyte maturation day . hCG use 3-18 follicle 0.2 mg triptorelin administer ≥ 19 follicle &gt; 11 mm observe . About 34-36 hour thereafter , oocyte retrieval followed IVF intra-cytoplasmic sperm injection ( ICSI ) perform . Two day oocyte pick-up 2 fresh embryo transfer . If patient high progesterone level day trigger ( progesterone level &gt; 2ng/ml ) , risk OHSS unfavorable endometrium , fresh transfer cancel freeze recommend . Patients use hCG final oocyte maturation receive luteal phase support progestogen gel ( 90 mg daily ) intra-vaginally estradiol ( 4 mg/day orally , twice daily ) initiate day oocyte retrieval day thereafter . Patients , use GnRH agonist trigger , fresh transfer intense luteal phase support estradiol progesterone ( receive intense luteal phase support estradiol progesterone dose mention progesterone 50 mg intramuscular injection per day ) . Assessments Patients return clinic pregnancy test 2 week embryo transfer . Local tolerance parameter ( pain , itching , swell redness ) assess clinical staff 30 min injection corifollitropin alfa FSH injection site . Clinical Outcome The primary objective show corifollitropin alfa regimen , term number oocytes retrieve , equivalent reference treatment ( predefined equivalence range : -3 +5 oocytes ) . Other clinical parameter also evaluate : dose FSH require , duration stimulation , number size follicle ( ≥11 , ≥15 ≥17 mm ) , serum hormone level , fertilization rate , number quality embryo obtain , implantation rate , miscarriage rate , pregnancy rate . At least 14 day embryo transfer , urinary pregnancy test perform . If pregnancy test positive , vaginal and/or abdominal ultrasonographic investigation perform 35 42 day ( 5 6 week ) embryo transfer confirm clinical pregnancy least 70 day ( ≥ 10 week ) embryo transfer confirm ongoing pregnancy . All efficacy analysis base intent-to-treat ( ITT ) population , include randomized patient receive corifollitropin alfa least one dose FSH Safety endpoint Occurrence adverse event , include moderate severe ovarian hyperstimulation syndrome ( OHSS ) , outcome local tolerance assessment evaluate safety endpoint . The percentage patient moderate severe OHSS compare treatment group use Fisher 's exact test . Safety analysis perform all-subjects-treated group , comprise patient receive either corifollitropin alfa FSH ,</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Each subject must willing able provide write informed consent study . Each subject must female year age ≥35 ≤42 time recruitment.. Each subject must indication controlled ovarian stimulation IVF Each subject must body weight ≥ 50.0 kg , body mass index ( BMI ) ≥18.0 ≤32.0 kg/m2 . Each subject must regular spontaneous menstrual cycle intraindividual variation outside 24 35 day range . For subject , ejaculatory sperm must available ( use donate and/or cryopreserved sperm allow ; sperm obtain via surgical sperm retrieval allow ) . Each subject must result clinical laboratory test ( complete blood count , blood chemistry , urinalysis ) within normal limit clinically acceptable investigator , measure local laboratory screening . A normal cervical smear result , obtain within 12 month , otherwise must obtain screening . Each subject must result physical examination , include blood pressure , within normal limit clinically acceptable limit investigator . Each subject must normal ovarian reserve , base antiMullerian hormon ( AMH ) 1.38 3.25ng/ml antral follicle count ( AFC ) 720 , take within 2 month prior corifollitropin alfa start . Each subject must able adhere dose visit schedule willing disclose medical event investigator . The subject recent ( ie , within 3 year ) history of/ current endocrine abnormality ( irrespective whether patient stabilize treatment ) . The subject history ovarian hyperresponse ( ie , previous IVF cycle 30 follicle ≥11 mm ultrasound ) ovarian hyperstimulation syndrome ( OHSS ) . The subject history of/or current polycystic ovary syndrome ( PCOS ) The subject 20 basal antral follicle &lt; 11 mm ( ovary combine ) measure ultrasound early follicle phase ( menstrual cycle day 25 ) . The subject le 2 ovary ovarian abnormality ( include endometrioma &gt; 10 mm ; visible ultrasound ) . The subject unilateral bilateral hydrosalpinx ( visible ultrasound , less clip ) . The subject intrauterine fibroid &gt; 5 cm clinically relevant pathology , could impair embryo implantation pregnancy continuation . The subject three unsuccessful treatment cycle IVF/ICSI . The subject history non low avarian response FSH / Human Menopausal Gonadotropin ( hMG ) treatment ( ie , previous COS cycle cancel due insufficient ovarian response ≤3 oocyte obtain ) . The subject history current miscarriage ( 3 , even explain ) . The subject FSH &gt; 15.0 IU/L LH &gt; 12 .0 IU/L measure local laboratory ( sample take early follicle phase : menstrual cycle day 2 5 ) . The subject test positive human immunodeficiency virus ( HIV ) Hepatitis B ( result obtain within one year ) . The subject contraindication use gonadotropin ( eg , tumor , pregnancy/lactation , undiagnosed vaginal bleeding , hypersensitivity , ovarian cyst ) GnRH antagonist ( eg , hypersensitivity , pregnancy/lactation ) . The subject concomitant use either LH hMG/urinary FSH preparation study cycle . The subject recent history of/or current epilepsy , thrombophilia , diabetes , cardiovascular , gastrointestinal , hepatic , renal pulmonary autoimmune disease require regular treatment . The subject sperm donor know gene defect , genetic abnormality , abnormal karyotyping , relevant current indication health offspring . The subject smoke recently stop smoking ( ie , within last 3 month prior sign ICF ) . The subject history presence alcohol drug abuse within 12 month prior sign inform consent . The subject allergy/ sensitivity investigational drug excipients . The subject use experimental drug within 3 month prior sign inform consent . The subject participate clinical study ( exclude survey ) .</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>